Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing
Abstract
Objectives: Favipiravir (T-705) shows potent in vitro activity but inconsistent in vivo efficacy. We assessed how plasma exposure and tissue distribution shape antiviral coverage using a tissue-based PK/PD framework.
Methods: Favipiravir and its hydroxylated metabolite (M1) were quantified in plasma and multiple organs of Syrian golden hamsters after single and repeated dosing and compared with a non-human primate dataset. We derived tissue penetration factors (TPFs), metabolic ratios (MR) and inhibitory quotients (IQ) against published EC50 values for representative RNA viruses and integrated these results with available human pharmacokinetic data.
Results: Favipiravir absorbed rapidly and distributed heterogeneously, reaching highest levels in kidney, gut and respiratory organs with limited brain access; M1 was enriched in liver and kidney. Organ exposure ranking was broadly similar across species. Tissue IQs were often lower than plasma IQs, indicating that plasma monitoring can overestimate target-organ coverage. IQ analysis suggested favourable coverage for influenza and RSV, heterogeneous, dose-dependent coverage for chikungunya, Rift Valley fever viruses and Orthohantavirus andesense (ANDV), intermediate coverage for Zika virus, and limited coverage for SARS-CoV-2, ebolavirus and West Nile virus. For some viruses, coverage may require higher exposures, prompting dose reassessment and safety data. The IQ patterns aligned with reported preclinical efficacy, and human pharmacokinetics suggested robust exposure margins for influenza but insufficient margins for SARS-CoV-2 and ebolavirus.
Conclusions: Tissue-based IQs refine the interpretation of exposure–response relationships and help explain favipiravir’s variable in vivo performance. The same framework can be refined and applied to other antiviral candidates to support preparedness strategies.
Related
- Integrative omics reveals candidate drug-repurposing targets in Tritrichomonas foetus
- Terminus est: Repurposing public RNA-seq data to map 3′ transcript termini in bacteria
- Repurposing, redefining, and reimagining: A paradigm shift towards person-driven neuroscience in the digital age
- FoldAbS: Repurposing the Protein Folding Model as a Foundation Encoder for Antibody Screening
- AgamOBP4-targeted drug repurposing identifies novel mosquito repellent scaffolds
BibTeX
@article{petit2026favipiravir,
title = {{Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing}},
author = {Paul-Rémi Petit and Franck Touret and Jean-Sélim Driouich and Albert Paré and Xavier de Lamballerie and Romain Marlin and Vanessa Contreras and Francis Relouzat and Anne-Sophie Gallouët and Quentin Pascal and Jérémie Guedj and Roger Le Grand and Antoine Nougairède and Caroline Solas},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
month = aug,
doi = {10.1093/jac/dkag224},
url = {https://hal.science/hal-05739229v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing
AU - Paul-Rémi Petit
AU - Franck Touret
AU - Jean-Sélim Driouich
AU - Albert Paré
AU - Xavier de Lamballerie
AU - Romain Marlin
AU - Vanessa Contreras
AU - Francis Relouzat
AU - Anne-Sophie Gallouët
AU - Quentin Pascal
AU - Jérémie Guedj
AU - Roger Le Grand
AU - Antoine Nougairède
AU - Caroline Solas
PY - 2026
DA - 2026/08/02
JO - Journal of Antimicrobial Chemotherapy
DO - 10.1093/jac/dkag224
UR - https://hal.science/hal-05739229v1
AB - Objectives: Favipiravir (T-705) shows potent in vitro activity but inconsistent in vivo efficacy. We assessed how plasma exposure and tissue distribution shape antiviral coverage using a tissue-based PK/PD framework. Methods: Favipiravir and its hydroxylated metabolite (M1) were quantified in plasma and multiple organs of Syrian golden hamsters after single and repeated dosing and compared with a non-human primate dataset. We derived tissue penetration factors (TPFs), metabolic ratios (MR) and inhibitory quotients (IQ) against published EC50 values for representative RNA viruses and integrated these results with available human pharmacokinetic data. Results: Favipiravir absorbed rapidly and distributed heterogeneously, reaching highest levels in kidney, gut and respiratory organs with limited brain access; M1 was enriched in liver and kidney. Organ exposure ranking was broadly similar across species. Tissue IQs were often lower than plasma IQs, indicating that plasma monitoring can overestimate target-organ coverage. IQ analysis suggested favourable coverage for influenza and RSV, heterogeneous, dose-dependent coverage for chikungunya, Rift Valley fever viruses and Orthohantavirus andesense (ANDV), intermediate coverage for Zika virus, and limited coverage for SARS-CoV-2, ebolavirus and West Nile virus. For some viruses, coverage may require higher exposures, prompting dose reassessment and safety data. The IQ patterns aligned with reported preclinical efficacy, and human pharmacokinetics suggested robust exposure margins for influenza but insufficient margins for SARS-CoV-2 and ebolavirus. Conclusions: Tissue-based IQs refine the interpretation of exposure–response relationships and help explain favipiravir’s variable in vivo performance. The same framework can be refined and applied to other antiviral candidates to support preparedness strategies.
SN - 0305-7453
SN - 1460-2091
ER -